SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure
14 references·0 citing·47 second hop
Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure (2016)Steady Increase In Prices For Oral Antica…Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011 (2015)Trends in the Cost and Use of…Pricing in the Market for Anticancer Drugs (2015)Pricing in the Market for Ant…Measuring the Value of Prescription Drugs (2015)Measuring the Value of Prescr…American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)American Society of Clinical …Indication-Specific Pricing for Cancer Drugs (2014)Indication-Specific Pricing f…Estimating The Health And Economic Burden Of Cancer Among Those Diagnosed As Adolescents And Young Adults (2014)Estimating The Health And Eco…The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts (2013)The price of drugs for chroni…Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists (2013)Prevalence of Off-Label Use a…Economic Burden of Cancer Survivorship Among Adults in the United States (2013)Economic Burden of Cancer Sur…Are survivors who report cancer‐related financial problems more likely to forgo or delay medical care? (2013)Are survivors who report canc…The High Cost of Cancer Drugs and What We Can Do About It (2012)The High Cost of Cancer Drugs…Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs (2009)Limits on Medicare's Ability …Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications (2006)Reimbursement for Cancer Trea…Consistent Covariance Matrix Estimation with Spatially Dependent Panel Data (1998)Consistent Covariance Matrix …Marriage protection and marriage selection—Prospective evidence for reciprocal effects of marital status and health (1996)The Financial Toxicity of Cancer Treatment: A Pilot Study Assessing Out-of-Pocket Expenses and the Insured Cancer Patient's Experience (2013)Population-Based Assessment of Cancer Survivors' Financial Burden and Quality of Life: A Prospective Cohort Study (2015)Self‐reported financial burden of cancer care and its effect on physical and mental health‐related quality of life among US cancer survivors (2016)Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies (2019)EuroQol - a new facility for the measurement of health-related quality of life (1990)The Role of Cost-effectiveness Analysis in Health and Medicine (1996)The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine (1996)Advanced therapy medicinal products: current and future perspectives (2016)Do patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund (2017)The high cost of prescription drugs: causes and solutions (2020)The theory and practice of econometrics (1986)A panel project on purchasing power parity: Mean reversion within and between countries (1996)The overvaluation of purchasing power parity (1998)Testing for Cross-Sectional Dependence in Panel-Data Models (2006)Robust Standard Errors for Panel Regressions with Cross-Sectional Dependence (2007)Effect of foreign direct investments, economic development and energy consumption on greenhouse gas emissions in developing countries (2018)The Medical Expenditure Panel Survey: a national health information resource. (1997)Annual Medical Expenditure and Productivity Loss Among Colorectal, Female Breast, and Prostate Cancer Survivors in the United States (2015)Assessment of Financial Burden as a Standard of Care in Pediatric Oncology (2015)Understanding, measuring, and addressing the financial impact of cancer on adolescents and young adults (2019)Male-Female Wage Differentials in Urban Labor Markets (1973)Projections of the Cost of Cancer Care in the United States: 2010-2020 (2011)Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries (2017)Rural-urban differences in financial burden among cancer survivors: an analysis of a nationally representative survey (2019)Understanding financial toxicity in head and neck cancer survivors (2019)Medical Bankruptcy in the United States, 2007: Results of a National Study (2009)Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia (2013)The Price of Inequality (2013)Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval (2017)The price of innovation: new estimates of drug development costs (2003)Cancer Drugs in the United States: Justum Pretium—The Just Price (2013)Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity (2014)Five Years of Cancer Drug Approvals (2015)Estimating Health Care Costs Related to Cancer Treatment From SEER-Medicare Data (2002)Cost of Care for Elderly Cancer Patients in the United States (2008)For Working-Age Cancer Survivors, Medical Debt And Bankruptcy Create Financial Hardships (2016)Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer (2018)Net Health Benefits (1998)Essential medicines for universal health coverage (2016)Financial Hardships Experienced by Cancer Survivors: A Systematic Review (2016)Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received (2016)Mental Accounting and Consumer Choice (1985)Fairness as a Constraint on Profit Seeking: Entitlements in the Market (2000)Mental Accounting and Consumer Choice (2008)The high price of anticancer drugs: origins, implications, barriers, solutions (2017)How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment (2021)
this work references cited by second hop

References

  • 1998Consistent Covariance Matrix Estimation with Spatially Dependent Panel Data6,815 cited
  • 2015American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options916 cited
  • 2013The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts592 cited
  • 2015Pricing in the Market for Anticancer Drugs452 cited
  • 2013Are survivors who report cancer‐related financial problems more likely to forgo or delay medical care?412 cited
  • 2009Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs391 cited
  • 2013Economic Burden of Cancer Survivorship Among Adults in the United States353 cited
  • 2012The High Cost of Cancer Drugs and What We Can Do About It255 cited
  • 2014Estimating The Health And Economic Burden Of Cancer Among Those Diagnosed As Adolescents And Young Adults200 cited
  • 2015Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011163 cited
  • 2015Measuring the Value of Prescription Drugs144 cited
  • 2014Indication-Specific Pricing for Cancer Drugs128 cited
  • 2013Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists127 cited
  • 2006

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

Reimbursement for Cancer Treatment: Coverage of Off-Label Drug Indications
81 cited

Cited by

No citing works inside the corpus for this window.